MedPath

Phase I study of DS-2741a in Healthy Volunteers and Subjects with Atopic Dermatitis

Phase 1
Terminated
Conditions
Healthy volunteers and Japanese subjects with moderate to severe atopic dermatitis.
Registration Number
JPRN-jRCT2080224983
Lead Sponsor
DAIICHI SANKYO Co., LTD.
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
terminated
Sex
All
Target Recruitment
75
Inclusion Criteria

< Part 1 and Part 3 >
1. Japanese healthy male subjects.
2. Age >=20 and <=45 years upon providing informed consent.
3. Body mass index (BMI) >=18.5 and <=25.0 kg/m2 at screening.

< Part 2 >
1. Japanese male or female, age >=20 upon providing informed consent.
2. Diagnosed with chronic atopic dermatitis at least 3 years before screening and by the criteria of Hannifin and Rajka at screening.

Exclusion Criteria

< Part 1 and Part 3 >
- Having a history of atopic dermatitis
- Having a history of hypersensitivity to drugs or other substances or being idiosyncratic
- Having alcohol or drug dependence
etc.

< Part 2 >
1. Having an active dermatological disease other than atopic dermatitis, which, in the investigator's opinion, would affect study assessments.
2. Having a history of serious disease in the study potentially endangering the subject, as judged by the investigator or sub-investigator.
3. Having a chronic or acute infection requiring treatment within 28 days before screening.
4. Having superficial skin infections within 7 days before screening.
5. Having a history of recurrent oral herpes and recurrent genital herpes.
6. Having a history of parasitic infection or invasive, opportunistic infection such as histoplasmosis despite infection resolution.
etc.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
safety<br>pharmacokinetics<br>Part 1 and Part 3: Safety<br>Part 2: Pharmacokinetics (PK)
Secondary Outcome Measures
NameTimeMethod
safety<br>pharmacokinetics<br>other<br>Part 1 and Part 3: PK, Anti-Drug Antibody (ADA)<br>Part 2: Safety, ADA
© Copyright 2025. All Rights Reserved by MedPath